» Articles » PMID: 38332246

Association of Circulating Tumor HPV16DNA Levels and Quantitative PET Parameters in Patients with HPV-positive Head and Neck Squamous Cell Carcinoma

Overview
Journal Sci Rep
Specialty Science
Date 2024 Feb 9
PMID 38332246
Authors
Affiliations
Soon will be listed here.
Abstract

Circulating tumor DNA (ctDNA), which circulates in the blood after being shed from cancer cells in the body, has recently gained attention as an excellent tumor marker. The purpose of this study was to evaluate whether ct human papillomavirus (HPV) 16 DNA (ctHPV16DNA) levels were associated with quantitative PET parameters in patients with HPV-positive head and neck (HN) squamous cell carcinoma (SCC). Fifty patients with oropharyngeal SCC (OPSCC) and 5 with SCC of unknown primary (SCCUP) before treatment were included. They all underwent blood sampling to test ctHPV16DNA levels and FDG PET-CT examinations. Quantitative PET parameters included SUVmax, metabolic tumor volume (MTV), MTV of whole-body lesions (wbMTV), and 56 texture features. ctHPV16DNA levels were compared to texture features of primary tumors in OPSCC patients (Group A) or the largest primary or metastatic lymph node lesions in OPSCC and SCCUP patients (Group B) and to other PET parameters. Spearman rank correlation test and multiple regression analysis were used to confirm the associations between ctHPV16DNA levels and PET parameters. ctHPV16DNA levels moderately correlated with wbMTV, but not with SUVmax or MTV in Groups A and B. ctHPV16DNA levels exhibited a weak negative correlation with low gray-level zone emphasis in Groups A and B. Multiple regression analysis revealed that wbMTV and high gray-level zone emphasis were the significant factors for ctHPV16DNA levels in Group B. These results were not observed in Group A. This study demonstrated that ctHPV16DNA levels correlated with the whole-body tumor burden and tumor heterogeneity visualized on FDG PET-CT in patients with HPV-positive HNSCC.

Citing Articles

Fibroblast Growth Factor Receptor (FGFR) Alterations in HPV Oropharyngeal Cancers.

Bhateja P, Liu X, Baliga S, Gogineni E, Jhawar S, Mitchell D J Med Virol. 2024; 96(11):e70086.

PMID: 39564895 PMC: 11600385. DOI: 10.1002/jmv.70086.


The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer.

Krsek A, Baticic L, Braut T, Sotosek V Biomolecules. 2024; 14(8).

PMID: 39199313 PMC: 11352962. DOI: 10.3390/biom14080925.


The landscape of circulating tumor HPV DNA and TTMV-HPVDNA for surveillance of HPV-oropharyngeal carcinoma: systematic review and meta-analysis.

Campo F, Iocca O, Paolini F, Manciocco V, Moretto S, De Virgilio A J Exp Clin Cancer Res. 2024; 43(1):215.

PMID: 39095868 PMC: 11297591. DOI: 10.1186/s13046-024-03137-1.


Pretreatment Circulating HPV16 DNA Viral Load Predicts Risk of Distant Metastasis in Patients with HPV16-Positive Oropharyngeal Cancer.

Mazurek A, Jablonska I, Kentnowski M, Kacorzyk U, Snietura M, Rutkowski T Cancers (Basel). 2024; 16(6).

PMID: 38539498 PMC: 10968812. DOI: 10.3390/cancers16061163.

References
1.
Lafata K, Corradetti M, Gao J, Jacobs C, Weng J, Chang Y . Radiogenomic Analysis of Locally Advanced Lung Cancer Based on CT Imaging and Intratreatment Changes in Cell-Free DNA. Radiol Imaging Cancer. 2021; 3(4):e200157. PMC: 8344351. DOI: 10.1148/rycan.2021200157. View

2.
Sullivan D, Obuchowski N, Kessler L, Raunig D, Gatsonis C, Huang E . Metrology Standards for Quantitative Imaging Biomarkers. Radiology. 2015; 277(3):813-25. PMC: 4666097. DOI: 10.1148/radiol.2015142202. View

3.
Kinahan P, Perlman E, Sunderland J, Subramaniam R, Wollenweber S, Turkington T . The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy. Radiology. 2020; 294(3):647-657. PMC: 7053216. DOI: 10.1148/radiol.2019191882. View

4.
Hanamoto A, Tatsumi M, Takenaka Y, Hamasaki T, Yasui T, Nakahara S . Volumetric PET/CT parameters predict local response of head and neck squamous cell carcinoma to chemoradiotherapy. Cancer Med. 2014; 3(5):1368-76. PMC: 4302687. DOI: 10.1002/cam4.295. View

5.
Cescon D, Bratman S, Chan S, Siu L . Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2022; 1(3):276-290. DOI: 10.1038/s43018-020-0043-5. View